Brief clinical trial results from the recent ESC meeting in Paris:
ARISTOTLE: Apixaban (factor Xa inhibitor) bests warfarin in preventing stroke in patients with non-valvular atrial fibrillation.
PRODIGY: Increased bleeding complications in patients taking 24 vs. 6 months of dual anti platelet therapy (aspirin + clopidogrel).
CORP: Colchicine prevents recurrent pericarditis.
ISAR-CABG: DES drug-eluting stents) beat BMS (bare metal stents) in SVG's at one year.
dal-VESSEL: Dalcetrapib raises HDL cholesterol but not blood pressure.
RUBY-1: No benefit of using factor Xa inhibitor in ACS
Read all about it here: http://www.escardio.org/congresses/esc-2011/congress-news/Pages/welcome.aspx